Natural Molecules as IKK α/β Inhibitors useful in the Treatment of Inflammation

Nadia Lampiasi and Giovanna Montana*
Institute of Biomedicine and Molecular Immunology “Alberto Monroy”, National Research Council, Italy

Abstract

Recently, there is a renewed interest in natural molecules used as protein kinase inhibitors with therapeutic potential. The possibility of obtaining these inhibitors from plants or vegetables, more safe compared to the synthetic one, represents a good target for the health demand. Natural compounds have been discovered to be effective in many disease treatments. Among these compounds are polyphenols and other natural molecules. They have been found to be able to interfere with many disease-related biochemical processes in vitro. They are capable of suppressing inflammation, tumor growth, bacterial infection, and virus infection. Thus, they have drawn great attention on the potential effects on disease prevention and treatment of carcinogenic, obesity, diabetic, and Alzheimer’s diseases. In this review, the potential of natural molecules is elucidated in detail with an overview of recent researches and these studies would suggest that IKK inhibitors could be excellent new therapeutics.

ABBREVIATIONS

IKK: IκB Kinase; LPS: Lip Poly Saccharide; NEMO: NF-κB Essential Modifier; IL6: Inter Leukin 6; TNFα: Tumor Necrosis Factor

INTRODUCTION

The IKK kinase β complex is one of the most studied of all protein kinases and it constitutes the protein kinases IKKα and IKKβ (also called IKK-1 and IKK-2) with a regulatory component called NEMO (NF-κB essential modifier) [1,2]. It has featured in over 10,000 papers since its discovery in 1998 due to its essential role in activating NF-κB, which is considered the ‘master’ transcription factor of inflammation. Indeed, the transcription factor NF-κB is known for its central role in inflammatory diseases and aberrant regulation of NF-κB has also been observed in autoimmune disorders and various types of cancer [1-4]. In fact, transcriptions of several proteins, which play important roles in the chronic inflammatory process, are mediated by NF-κB [5,6]. These proteins include cytokines such as IL-6 and IL-8; adhesion molecules such as E-selectin, intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), the enzymes nitric oxide synthase (NOS) and cyclooxygenase-2 (COX-2) [7]. Therefore, targeting the activation of NF-κB-dependent transcription by pharmacologic agents may prove to be quite useful in the treatment of inflammatory disorders. NF-κB frequently exists as a p65-p50 hetero dimer in the cytoplasm in an inactive state complex with inhibitor of kappa B protein (IκB). Binding of IκB protein to the NF-κB prevents its translocation to the nucleus and modulates its transcriptional function. All IκB proteins contain six ankyrin repeat domain (ARD) that is responsible for interaction surface around the NF-κB dimer and a signal responsive domain (SRD) that contains phosphorylation and ubiquitination sites for signal responsive degradation. Degradation of IκB regulates specific phosphorylation by activating IκB kinase (IKK) proteins results in activation or translocation of NF-κB to nucleus. The mammalian transcriptional factor (NF-κB) family consist of five major members such as RelA (p65), RelB, c-Rel, p50 (NF-κB1) and p52 (NF-κB2). All five members have a distinctive feature: the conserved Rel Homology Domain (RHD). The dimer binds to the κB sites in DNA of their target genes and forms homo or heterodimeric DNA-binding complexes. The Rel Homology Domain is a distinctive feature of eukaryotic transcription factors, such as, NF-κB, Dorsal, and Relish. RHD can be subdivided into two domains: N-terminal DNA binding motif that functions as a dimerization domain; the C-terminal dimerization domain, contains the site for interaction with NIK or NF-κB-p-regulating kinase. There are two pathways of interest related to NF-κB activation: canonical and alternate, both involve ubiquitination of repressors; phosphorylation and degradation of the inhibitory IκB proteins (IκBα) by NEMO/IKK-α/IKK-β complex or with semi proteolysis of p100 (for non canonical pathway). NIK phosphorylates IKK-α which phosphorylates and attaches ubiquitin marker on the C-terminal end of p-100. The partial proteolysis of p100 frees p52/ RelB to be transported to nucleus [8]. In 1996, the biochemical
identification and purification of the serine/threonine kinase IkB kinase, i.e. IKK complex [9,10], IKK was defined through its ability to catalyze the phosphorylation of the serines in the N-terminal regulatory region on IkBα and IkBβ, as well as its rapid activation in response to cell stimulated by TNF-α, IL-1 or LPS. These studies resulted in the identification of three IKK subunits, two catalytic subunits such as IKKa (or IKK-1) and IKKβ (or IKK-2) and a regulatory subunit IKKγ, also called NEMO or IKKAP1 [11]. IKKα is an 85-kD protein, which was initially identified as a serine threonine kinase of unknown function, named CHUK, conserved helix-loop-helix ubiquitous kinase, in a search for cDNAs related to cMyC. The second catalytic subunit, IKKβ is an 87-kD protein related to IKKα [12,13]. Both subunits, which are 52% identical, contain an N-terminal kinase domain, a leucine zipper (LZ) and a helix-loop-helix (HLH). IKKγ is present as a 50-52-kD doublet, containing several N-terminal helical regions coiled-coil repeat motifs, a LZ and a Zn-finger at its C-terminus. The IKK complex is both a signaling hub for NF-kB activation and an interface for crosstalk between NF-kB activating pathways and other physiological processes. The IKKs generally serve to transduce pro-inflammatory- and growth-stimulating signals that contribute to major cellular processes, but also play a key role in the pathogenesis of a number of human diseases. There is ample evidence that IKK activity is not restricted to NF-kB-dependent pathways but can also mediate cross talk with other signaling cascades, such as mTOR and MAPK pathways [14]. The importance of protein kinases inhibitors as potential drug targets is become most important over the past two decades. Therefore, the catalytic IKKs represent attractive targets for intervention with small molecule kinase inhibitors. Many studies are looking to synthesize new series of IKK-1 and IKK-2 inhibitors. The 4(2-aminoethyl) amino-1, 8-dimethylimidazo (1,2-a) quinoxaline (BMS-345541) is a standard of comparison between IKK inhibitors and showed highly selective IKK-2 inhibition (Figure 1). In fact, it was identified as a selective inhibitor of the catalytic subunits of IKK with different affinity (IKK-2 IC₅₀ = 0.3 μM, IKK-1 IC₅₀ = 4 μM). However, the compound has a remarkable specificity since it failed to inhibit a panel of 15 other kinases. Indeed, it selectively inhibited the induction of IkBα phosphorylation in cells (IC₅₀ = 4μM), while failing to affect c-Jun and STAT3 phosphorylation, as well as mitogen-activated protein kinase-activated protein kinase 2 activation in cells [15]. It has been proposed a binding model in which BMS-345541 binds to similar allosteric sites on IKK-1and IKK-2, which then affects the active sites of the subunits differently. Docking studies in the IKK-2 binding site was performed in order to determine the residues implicated in the binding for a better IKK-2 inhibition activity [15]. Most of the FDA-approved protein kinase inhibitors are competitive with respect to the ATP. Many protein kinase inhibitors bind to their target enzyme by forming 1-3 hydrogen bonds with the hinge residues, while interacting with the residues that make up the adenine binding site and hydrophobic pockets I or II. This review focuses on the therapeutic potential of natural molecules as protein kinase inhibitors and highlights the mechanisms of these compounds against inflammation because natural product extracts such as plants, have low toxicity, minor side-effects, and they are more cost-effective than chemical drugs. It is of paramount importance to identify new natural, effective, and affordable anti-IKK agents suitable for beneficial in human health.

Mechanisms of IKK activation

IkB kinases are activated by a plethora of agents and conditions, including extracellular ligand that bind membrane receptors, such as TNFR, TLR, or IL-1R, intracellular stress, such as DNA damage and reactive oxygen species, as well as the recognition of intracellular pathogens mediated by the NOD. Protein phosphorylation, non degradative ubiquitination, adapter protein interactions and most likely higher order oligomerization events all contribute to IKK activation. IKK activation in mammalian cells requires the presence of the IKK, NEMO, IKK AP1 regulatory subunits. Mouse cells deficient in this protein fail to phosphorylates and degrade IkBs and consequently to activate NF-kB as a result of divergent stimuli including TNFα, IL-1 and LPS. In mammalian cells, as well as in insect cells, activation of IKK depends on the phosphorylation of its catalytic subunits. Treatment of IKK complexes, purified from TNF-stimulated cells with protein phosphatase 2A (PP2A), abolishes their catalytic activity [16]. In addition, treatment of cells with okadaic acid, a specific PP2A inhibitor, results in the accumulation of active IKK and in turn in activation of NF-kB. These results were the first to indicate that IKKB, but not IKKa, is the target for pro-inflammatory signals. However, since the activation loops of IKKa and IKKB are identical (Figure 2) and their kinase domains are highly similar, it is plausible that IKKa could serve as a target for a different class of signals. The activities of IKKα and IKKβ are also modulated by their C-terminal HLH motifs. Mutations disrupting the α-helical structures within these motifs in either sub units dramatically decrease kinase activity, without interfering with dimerization or complex assembly [17,18]. Initially, it was proposed that the HLH motif was a binding site for regulatory subunits such as IKKy, but it soon became clear that this is not the way it functions. Most importantly, the HLH mutations were found to have devastating effects on activities of recombinant IKKα or IKKβ not associated with any other subunit [18]. Recently, the HLH motif of IKKB was found to directly interact with the kinase domain and stimulate its activity involved in the control of epidermal differentiation. Deletion mutant containing amino acids 559, but lacking the

Figure 1 BMS-345541 is a potent, selective, and allosteric site-binding inhibitor of IKK β (IKK-2) and shows 10 times greater selectivity over IKK α (IKK-1).
C-terminal region, is completely inactive when expressed in either mammalian or insect cells. The HLH motif is an intrinsic activator of the IKKβ when extensively phosphorylates at its C-terminal region. The C-terminal phospho-acceptor sites are located between amino acids 670 and 705 and their phosphorylation down regulates kinase activity. The accumulation of negative charges in the C-terminal region of IKKβ are weak the interaction between the HLH motif and the kinase domain.

The development of small natural molecule inhibitors of the IKKs

For centuries, the only effective way to relieve pain and cure diseases has been the use (either by oral or topical administrations) of natural products, mainly of vegetal origin. The first record of using plants is to treat illnesses come from Mesopotamia and date from about 2600 BC. Later, older western civilizations such as the Egyptians with the Ebers Papyrus dating from 1500 BC, the Greeks with the History of Plants from Theophrastus dating from 300 BC and also the Romans with the De materia medica from Pedanius Dioscorides written between 65 and 75 AD, documented naturally drugs. Oriental civilizations such as those in China and in India have also extensively documented the medicinal use of endemic plants since ancient times. For example, Wu Shi Er Bing Fang reported 52 prescriptions around 1100 BC, and the Indian Ayurvedic system dates from about 1000 BC. These reports are the basis of traditional medicines that are extensively used today. One of the most notable effects of certain medicinal plants is their anti-inflammatory activity. In recent years the use of specific database allowed the search for IKK-2 inhibitors of natural origin that compete with ATP [19]. Analysis of these natural products revealed that some of them are polyphenols, which are secondary metabolic products in plants, whose roles as antioxidants and in the prevention of degenerative diseases such as the biflavonoid ayanin, which is found in seven extracts and has been claimed to be of use in treating allergic asthma [20].

Based on early studies that identified IKKβ as the key driver of classical NF-kB signalling, large pharmaceutical companies have developed diverse, large-scale, high-throughput screening (HTS) programmes encompassing hit-to-lead development and characterization of structure–activity relationships (SAR), all in the absence of resolved crystal structures for IKKα and IKKβ. This has led to a number of chemical entities of relatively low molecular weight with drug-like features that commonly function as IKKβ selective inhibitors. Majority of these compounds perform as adenosine triphosphate (ATP) - competitive molecules or alternatively possess allosteric action to limit IKK activities.

Furthermore, a number of these molecules have been pursued in vivo animal models of disease (Table 1). The most significant phenolic compounds found in these 36 anti-inflammatory extracts are as follows:

The isoflavone iristectorigenin A and the anthocyanin malvidin, which show strong inhibitory activity against NO production [21,22] are found in Iris germanica extracts and in Lavandula angustifolia and in Vaccinium myrtillus extracts, respectively. The flavone baicalein [21], which is found in

| Table 1: List of The most significant phenolic compounds found in anti-inflammatory extracts. |
|-----------------------------------|-------------------------------|
| Malvidin                          | Iristectorigenina             |
| Baicalein                         | Epicatechin                   |
| Aristolactam                      | Harmol                        |
| Ferulic acid                      |                               |

Figure 2 Scheme of the IKKb domain structure.
ULD: Ubiquitin-Like Domain; LZ: Leucine Zipper; HLH: Helix-Loop-Helix domain; NBD, NEMO-Binding Domain. Numbering of domain borders differ slightly between different references. The catalytic active site lysine residue (K44) is indicated and the two serine-residues (S177/S181) of the activation loop, which are phosphorylated upon activation, are shown in italics.
**DISCUSSION & CONCLUSION**

**Conclusions**

IKK-β plays a crucial role in the control of NF-κB activity. The efforts to investigate natural compounds involved in the IKK-β inhibition is allowed by the crystallographic structure and by using a computational approach involving Homology Modelling, Molecular Docking and Pharmacophore/3D-QSAR analysis. Data suggest that molecular mechanism involved in the IKK-β inhibition is similar to that observed in the case of other kinase proteins, the formation of a ligand-receptor complex able to mimic ATP or the natural substrate kinase proteins. Computational approaches have revealed the presence of three broad hydrophobic pockets able to accept a steric hindrance and a loop constituted by residues Glu97, Tyr98, Cys99, Glu100, Gly101, and Gly102 that is involved in the formation of several hydrogen bonds with each ligand. The Molecular Docking approach shows that the presence of a central aromatic ring and a side chain group are common features of all classes of inhibitors.

**REFERENCES**


13. Woronicz JD, Gao X, Cao Z, Rothe M, Goeddel DV. IkappaB kinase-beta:


